Atea Pharmaceuticals, Inc. (AVIR) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AVIR Revenue Growth
AVIR Revenue Analysis (2018–2025)
As of May 8, 2026, Atea Pharmaceuticals, Inc. (AVIR) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, AVIR's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $351.4 million in 2021.
When compared to Healthcare sector peers including IOVA (+34.3% YoY), RDVT (+18.1% YoY), and RLAY (+39.0% YoY). Compare AVIR vs IOVA →
AVIR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AVIRCurrent | $0 | - | - | - | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 RDVT | $90M | +18.1% | +21.1% | 14.6% | |
 RLAY | $15M | +39.0% | -28.6% | -1971.6% | |
 ABUS | $14M | +128.2% | +15.3% | -271.0% |
AVIR Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-180,887,000 | - |
| 2024 | $0 | - | $-83,367,000 | - | $-192,950,000 | - |
| 2023 | $0 | - | $-70,090,000 | - | $-164,162,000 | - |
| 2022 | $0 | -100.0% | $-62,390,000 | - | $-130,650,000 | - |
| 2021 | $351.4M | +622.5% | $184.2M | 52.4% | $138.4M | 39.4% |
| 2020 | $48.6M | - | $10.6M | 21.8% | $-11,030,000 | -22.7% |
| 2019 | $0 | - | $-17,000 | - | $-14,608,000 | - |
| 2018 | $0 | - | $-17,000 | - | $-9,477,000 | - |
See AVIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVIR — Frequently Asked Questions
Quick answers to the most common questions about buying AVIR stock.
Is AVIR's revenue growth accelerating or slowing?
AVIR TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is AVIR's long-term revenue growth rate?
Atea Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is AVIR's revenue distributed by segment?
AVIR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.